EEF1B2

Summary

EEF1B2 (eukaryotic translation elongation factor 1 beta 2, HGNC:3208) is a protein-coding gene on chromosome 2q33.3, encoding Elongation factor 1-beta (P24534). Catalytic subunit of the guanine nucleotide exchange factor (GEF) (eEF1B subcomplex) of the eukaryotic elongation factor 1 complex (eEF1). It is a common-essential gene (DepMap: required in 97.4% of cancer cell lines).

This gene encodes a translation elongation factor. The protein is a guanine nucleotide exchange factor involved in the transfer of aminoacylated tRNAs to the ribosome. Alternative splicing results in three transcript variants which differ only in the 5’ UTR.

Source: NCBI Gene 1933 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Strong, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 42 total — 3 pathogenic
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 97.4% of screened cell lines (common-essential)
• MANE Select transcript: NM_001959

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3208
Approved symbol	EEF1B2
Name	eukaryotic translation elongation factor 1 beta 2
Location	2q33.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000114942
Ensembl biotype	protein_coding
OMIM	600655
Entrez	1933

Gene structure

Transcript identifiers

Ensembl transcripts: 25 — 18 protein_coding, 4 nonsense_mediated_decay, 3 retained_intron

ENST00000236957, ENST00000392222, ENST00000415904, ENST00000429769, ENST00000435123, ENST00000445505, ENST00000455150, ENST00000460760, ENST00000479587, ENST00000482103, ENST00000881936, ENST00000881937, ENST00000881938, ENST00000881939, ENST00000881940, ENST00000924252, ENST00000924253, ENST00000924254, ENST00000924255, ENST00000924256, ENST00000924257, ENST00000924258, ENST00000924259, ENST00000924260, ENST00000955596

RefSeq mRNA: 3 — MANE Select: NM_001959 NM_001037663, NM_001959, NM_021121

CCDS: CCDS2367

Canonical transcript exons

ENST00000392222 — 6 exons

Exon	Start	End
ENSE00000784964	206160588	206160710
ENSE00001511145	206159895	206160059
ENSE00003490949	206162729	206162928
ENSE00003503937	206162489	206162614
ENSE00003526150	206161346	206161472
ENSE00003596204	206162038	206162104

Expression profiles

Bgee: expression breadth ubiquitous, 138 present calls, max score 99.75.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 353.5572 / max 3035.4350, expressed in 1827 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
24823	294.4619	1826
24822	48.9465	1817
202545	8.5642	1673
202546	1.5846	845

Top tissues by expression

138 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
body of pancreas	UBERON:0001150	99.75	gold quality
calcaneal tendon	UBERON:0003701	99.74	gold quality
left ovary	UBERON:0002119	99.69	gold quality
cortical plate	UBERON:0005343	99.69	gold quality
ovary	UBERON:0000992	99.68	gold quality
pancreas	UBERON:0001264	99.68	gold quality
islet of Langerhans	UBERON:0000006	99.65	gold quality
lymph node	UBERON:0000029	99.65	gold quality
colonic epithelium	UBERON:0000397	99.65	gold quality
skin of abdomen	UBERON:0001416	99.65	gold quality
right ovary	UBERON:0002118	99.65	gold quality
endocervix	UBERON:0000458	99.64	gold quality
granulocyte	CL:0000094	99.63	gold quality
zone of skin	UBERON:0000014	99.63	gold quality
body of uterus	UBERON:0009853	99.62	gold quality
skin of leg	UBERON:0001511	99.61	gold quality
esophagus mucosa	UBERON:0002469	99.61	gold quality
bone marrow	UBERON:0002371	99.60	gold quality
small intestine Peyer’s patch	UBERON:0003454	99.60	gold quality
fallopian tube	UBERON:0003889	99.60	gold quality
ectocervix	UBERON:0012249	99.60	gold quality
vagina	UBERON:0000996	99.59	gold quality
mammary gland	UBERON:0001911	99.59	gold quality
spleen	UBERON:0002106	99.59	gold quality
thoracic mammary gland	UBERON:0005200	99.59	gold quality
omental fat pad	UBERON:0010414	99.59	gold quality
bone marrow cell	CL:0002092	99.58	gold quality
myometrium	UBERON:0001296	99.58	gold quality
duodenum	UBERON:0002114	99.58	gold quality
esophagus	UBERON:0001043	99.57	gold quality

Single-cell (SCXA)

Detected in 9 experiment(s), a significant marker in 6.

Experiment	Marker?	Max mean expression
E-GEOD-89232	yes	4690.22
E-GEOD-81547	yes	20.00
E-MTAB-9067	yes	11.09
E-MTAB-9801	yes	8.62
E-MTAB-6678	yes	4.94
E-MTAB-10596	no	2585.73
E-ANND-5	no	699.80
E-ENAD-27	no	6.56
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 97.4% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 9)

• TCTP preferentially stabilized the GDP form of eEF1A, and, furthermore, impaired the GDP exchange reaction promoted by eEF1Bbeta. (PMID:14623968)
• Results indicate an evolutionary lineage of translation initiation factor eIF2alpha/gamma from the functionally related elongation factor eEF1Balpha/eEF1A complex. (PMID:15341733)
• Cathepsin D and eEF1 are promising markers for the detection of cellular senescence induced by a variety of treatments. (PMID:19487283)
• Both eEF1A1 and eEF1A2 colocalise with all eEF1B subunits, in such close proximity that they are highly likely to be in a complex. (PMID:25436608)
• It has been postulated that the N-terminus region of EF1beta may be responsible for its dimerization and the C-terminus region of this protein modulates the formation of an ordered EF1beta-gamma oligomer, a structure that may be essential in the elongation step of eukaryotic protein biosynthesis. (PMID:29572982)
• high eEF1Balpha expression is associated with poor overall survival and may serve as an independent prognostic factor of gastric cancer. (PMID:30572058)
• the protein-binding domain of eEF1Bbeta shows flexible spatial organization which may be needed for interaction with eEF1Bgamma or other protein partners. (PMID:30590147)
• New evidence that biallelic loss of function in EEF1B2 gene leads to intellectual disability. (PMID:31845318)
• Proteogenomics Integrating Novel Junction Peptide Identification Strategy Discovers Three Novel Protein Isoforms of Human NHSL1 and EEF1B2. (PMID:34420305)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	eef1b2	ENSDARG00000044521
mus_musculus	Eef1b2	ENSMUSG00000025967
rattus_norvegicus	AABR07006688.2	ENSRNOG00000031628
drosophila_melanogaster	eEF1beta	FBGN0028737
drosophila_melanogaster	eEF1delta	FBGN0032198
caenorhabditis_elegans		WBGENE00018846

Paralogs (2): EEF1D (ENSG00000104529), EFCC1 (ENSG00000114654)

Protein

Protein identifiers

Elongation factor 1-beta — P24534 (reviewed: P24534)

Alternative names: eEF-1B alpha

All UniProt accessions (5): P24534, C9JZW3, F2Z2G2, F8WF65, F8WFC9

UniProt curated annotations — full annotation on UniProt →

Function. Catalytic subunit of the guanine nucleotide exchange factor (GEF) (eEF1B subcomplex) of the eukaryotic elongation factor 1 complex (eEF1). Stimulates the exchange of GDP for GTP on elongation factor 1A (eEF1A), probably by displacing GDP from the nucleotide binding pocket in eEF1A.

Subunit / interactions. EF-1 is composed of 4 subunits: alpha, beta (alpha subunit of the eEF1B subcomplex), delta (beta subunit of the eEF1B subcomplex), and gamma (gamma subunit of the eEF1B subcomplex). Interacts with elongation factor EEF1A1.

Post-translational modifications. Phosphorylation affects the GDP/GTP exchange rate.

Induction. By homocysteine (HC), may mediate accelerated synthesis of free thiol-containing proteins in response to HC-induced oxidative stress.

Similarity. Belongs to the EF-1-beta/EF-1-delta family.

RefSeq proteins (3): NP_001032752, NP_001950, NP_066944 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001326	Transl_elong_EF1B_B/D_CS	Conserved_site
IPR014038	EF1B_bsu/dsu_GNE	Domain
IPR014717	Transl_elong_EF1B/ribsomal_bS6	Homologous_superfamily
IPR018940	EF-1_beta_acid_region_euk	Domain
IPR036219	eEF-1beta-like_sf	Homologous_superfamily
IPR036282	Glutathione-S-Trfase_C_sf	Homologous_superfamily
IPR049720	EF1B_bsu/dsu	Family

Pfam: PF00736, PF10587

UniProt features (30 total): modified residue 8, helix 7, strand 7, turn 2, initiator methionine 1, chain 1, cross-link 1, domain 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
5DQS	X-RAY DIFFRACTION	2.1
1B64	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P24534-F1	77.83	0.17

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (9): 95, 106, 174, 147, 7, 8, 42, 88, 93

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-156842	Eukaryotic Translation Elongation

MSigDB gene sets: 284 (showing top): GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_DN, GOBP_RESPONSE_TO_ETHANOL, HORIUCHI_WTAP_TARGETS_DN, SWEET_KRAS_ONCOGENIC_SIGNATURE, GCM_MSN, MODULE_151, GCM_NPM1, MODULE_150, HSIAO_HOUSEKEEPING_GENES, DARWICHE_SKIN_TUMOR_PROMOTER_UP, DARWICHE_PAPILLOMA_RISK_LOW_UP, DARWICHE_PAPILLOMA_RISK_HIGH_UP, DARWICHE_SQUAMOUS_CELL_CARCINOMA_UP, MODULE_149, COUP_01

GO Biological Process (3): translational elongation (GO:0006414), response to ethanol (GO:0045471), translation (GO:0006412)

GO Molecular Function (3): translation elongation factor activity (GO:0003746), guanyl-nucleotide exchange factor activity (GO:0005085), protein binding (GO:0005515)

GO Cellular Component (5): cytoplasm (GO:0005737), cytosol (GO:0005829), eukaryotic translation elongation factor 1 complex (GO:0005853), endoplasmic reticulum (GO:0005783), protein-containing complex (GO:0032991)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Translation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	3
macromolecule biosynthetic process	2
translational elongation	2
cellular anatomical structure	2
translation	1
response to alcohol	1
peptidyltransferase activity	1
translational initiation	1
translational termination	1
protein metabolic process	1
protein biosynthetic process	1
translation factor activity	1
GTP binding	1
GDP binding	1
GTPase regulator activity	1
binding	1
intracellular anatomical structure	1
protein-containing complex	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cellular_component	1

Protein interactions and networks

STRING

3257 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
EEF1B2	EEF1G	P26641	999
EEF1B2	EEF1A1	P04719	998
EEF1B2	EEF1D	P29692	982
EEF1B2	EEF1A2	P54266	907
EEF1B2	EEF2	P13639	757
EEF1B2	TSFM	P43897	695
EEF1B2	VARS1	P26640	662
EEF1B2	HPGDS	O60760	646
EEF1B2	EIF4A1	P04765	643
EEF1B2	EIF4A2	Q14240	642
EEF1B2	EEF1E1	O43324	642
EEF1B2	KTN1	Q86UP2	642
EEF1B2	VARS2	Q5ST30	551
EEF1B2	RABIF	P47224	541
EEF1B2	EIF3E	P60228	538

IntAct

183 interactions, top by confidence:

A	B	Type	Score
EEF1B2	EEF1G	psi-mi:“MI:0915”(physical association)	0.890
EEF1G	EEF1B2	psi-mi:“MI:0914”(association)	0.890
EEF1A2	EEF1B2	psi-mi:“MI:0914”(association)	0.740
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
EEF1B2	HTT	psi-mi:“MI:0915”(physical association)	0.670
EEF1G	EEF1B2	psi-mi:“MI:0915”(physical association)	0.560
EEF1B2	EEF1G	psi-mi:“MI:0915”(physical association)	0.560
EEF1B2	SPRYD4	psi-mi:“MI:0915”(physical association)	0.560
DLD	PDHB	psi-mi:“MI:0914”(association)	0.530
ATF3	MYL6B	psi-mi:“MI:0914”(association)	0.530
MLLT6	RGPD8	psi-mi:“MI:0914”(association)	0.530
EEF1G	INPPL1	psi-mi:“MI:0914”(association)	0.530
EEF1A1	ZPR1	psi-mi:“MI:0914”(association)	0.530

BioGRID (296): EEF1B2 (Affinity Capture-MS), EEF1G (Two-hybrid), EEF1B2 (Affinity Capture-RNA), EEF1B2 (Affinity Capture-RNA), EEF1B2 (Affinity Capture-RNA), EEF1B2 (Affinity Capture-MS), EEF1B2 (Affinity Capture-MS), EEF1B2 (Affinity Capture-MS), EEF1B2 (Affinity Capture-MS), EEF1G (Two-hybrid), AHNAK (Co-fractionation), ATL3 (Co-fractionation), EEF1A1 (Co-fractionation), EEF1B2 (Co-fractionation), EEF1B2 (Co-fractionation)

ESM2 similar proteins: A0A3L6DPG1, A4QVI3, A6IPG1, B0BN85, B4JXU2, B5XEX1, C0HBG1, C1BH56, C3YFB4, F4HQD4, O22785, O42766, O70251, P15705, P17624, P23231, P24534, P26446, P29412, P34826, P35189, Q08446, Q0JL44, Q11118, Q23280, Q2KIK0, Q3T168, Q43468, Q4R4P3, Q4SK88, Q4WTC0, Q5E983, Q5R6Z8, Q5RHR0, Q5ZIN1, Q6AYK6, Q6AZB3, Q6AZN0, Q7Q9C0, Q94BR4

Diamond homologs: A5D989, A6IPG1, O70251, O74173, O81918, O96827, P12262, P24534, P29412, P29522, P29545, P29546, P29692, P29693, P30151, P32192, P32471, P34460, P34826, P34827, P48006, P53787, P57776, P78590, P93447, Q40680, Q40682, Q4R3D4, Q5E983, Q658K8, Q68FR9, Q69BZ7, Q6DET9, Q717R8, Q84WM9, Q9GRF8, Q9SCX3, Q9SI20, Q9U2H9, Q9VL18

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
EEF1B2	“form complex”	“EEF1B complex”	binding
CSNK2A1	unknown	EEF1B2	phosphorylation
CSNK2A2	unknown	EEF1B2	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 165 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Signaling by ALK fusions and activated point mutants	7	9.7×	3e-03
Signaling by Interleukins	10	5.9×	3e-03
Cytokine Signaling in Immune system	12	4.5×	4e-03

GO biological processes:

GO term	Partners	Fold	FDR
intrinsic apoptotic signaling pathway	7	17.9×	8e-05
translational initiation	6	15.4×	8e-04
mitophagy	6	13.6×	1e-03
autophagosome maturation	5	12.5×	6e-03
G1/S transition of mitotic cell cycle	7	10.0×	1e-03
autophagosome assembly	6	9.6×	5e-03
DNA damage response	11	4.2×	7e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

42 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	0
Uncertain significance	26
Likely benign	3
Benign	1

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
1332885	NM_001959.4(EEF1B2):c.80+1G>C	Pathogenic
1332886	NM_001959.4(EEF1B2):c.185dup (p.Tyr62Ter)	Pathogenic
689450	NM_001959.4(EEF1B2):c.383C>A (p.Ser128Ter)	Pathogenic

SpliceAI

882 predictions. Top by Δscore:

Variant	Effect	Δscore
2:206160055:GAGGG:G	donor_gain	1.0000
2:206160057:GGG:G	donor_gain	1.0000
2:206160058:GG:G	donor_gain	1.0000
2:206160058:GGG:G	donor_gain	1.0000
2:206160059:GG:G	donor_gain	1.0000
2:206160060:G:GA	donor_loss	1.0000
2:206160061:T:G	donor_loss	1.0000
2:206160585:CAGG:C	acceptor_loss	1.0000
2:206160586:A:C	acceptor_loss	1.0000
2:206160587:GGT:G	acceptor_gain	1.0000
2:206160587:GGTAT:G	acceptor_gain	1.0000
2:206160700:G:GT	donor_gain	1.0000
2:206160701:A:T	donor_gain	1.0000
2:206160708:CAGGT:C	donor_loss	1.0000
2:206160709:AGGTA:A	donor_loss	1.0000
2:206160711:G:A	donor_loss	1.0000
2:206160712:T:A	donor_loss	1.0000
2:206161343:A:AG	acceptor_gain	1.0000
2:206161344:A:AG	acceptor_gain	1.0000
2:206161345:G:GG	acceptor_gain	1.0000
2:206161469:GGAG:G	donor_gain	1.0000
2:206161470:G:GT	donor_gain	1.0000
2:206161471:AGGTA:A	donor_loss	1.0000
2:206161473:G:GC	donor_loss	1.0000
2:206161474:T:G	donor_loss	1.0000
2:206162034:A:AG	acceptor_gain	1.0000
2:206162036:A:AG	acceptor_gain	1.0000
2:206162036:AG:A	acceptor_gain	1.0000
2:206162037:G:A	acceptor_loss	1.0000
2:206162037:G:GA	acceptor_gain	1.0000

AlphaMissense

1481 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:206160670:T:A	W55R	1.000
2:206160670:T:C	W55R	1.000
2:206162530:A:G	K147E	1.000
2:206162532:A:C	K147N	1.000
2:206162532:A:T	K147N	1.000
2:206162534:C:A	P148H	1.000
2:206162536:T:A	W149R	1.000
2:206162536:T:C	W149R	1.000
2:206162576:T:A	V162D	1.000
2:206162605:T:A	W172R	1.000
2:206162605:T:C	W172R	1.000
2:206162747:G:A	G181E	1.000
2:206162765:T:C	L187P	1.000
2:206162783:T:A	V193D	1.000
2:206162788:G:C	D195H	1.000
2:206162850:G:C	Q215H	1.000
2:206162850:G:T	Q215H	1.000
2:206162869:T:C	F222L	1.000
2:206162871:C:A	F222L	1.000
2:206162871:C:G	F222L	1.000
2:206161452:T:C	F104L	0.999
2:206161454:T:A	F104L	0.999
2:206161454:T:G	F104L	0.999
2:206162508:G:C	K139N	0.999
2:206162508:G:T	K139N	0.999
2:206162509:T:C	S140P	0.999
2:206162510:C:T	S140F	0.999
2:206162512:T:C	S141P	0.999
2:206162516:T:A	I142N	0.999
2:206162516:T:G	I142S	0.999

dbSNP variants (sampled 300 via entrez): RS1000178857 (2:206159395 C>A,G,T), RS1000965132 (2:206158425 T>C), RS1001271223 (2:206158208 C>A,T), RS1001638994 (2:206163072 T>C), RS1001719577 (2:206157854 C>T), RS1002046580 (2:206158998 G>A,C,T), RS1002736599 (2:206160853 A>G), RS1003365375 (2:206160478 C>A,G,T), RS1003758917 (2:206159644 G>A,C,T), RS1004150430 (2:206162413 T>C,G), RS1004945256 (2:206160298 C>A), RS1005297030 (2:206159887 C>G,T), RS1005321496 (2:206161558 G>A), RS1006314251 (2:206160959 G>A), RS1006582387 (2:206160448 C>T)

Disease associations

OMIM: gene MIM:600655 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
neurodevelopmental disorder	Strong	Autosomal recessive

Mondo (2): intellectual disability (MONDO:0001071), neurodevelopmental disorder (MONDO:0700092)

Orphanet (1): NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST005951_45	Body mass index	1.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295731 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.18	Kd	661.5	nM	CHEMBL5653589
6.18	ED50	661.5	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 3 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2147935: Binding affinity to human EEF1B2 incubated for 45 mins by Kinobead based pull down assay	kd	0.6615	uM

CTD chemical–gene interactions

58 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	4
Cadmium Chloride	decreases expression, increases abundance, increases expression	3
Arsenic Trioxide	affects binding, decreases reaction, affects cotreatment, decreases expression	2
Arsenic	affects cotreatment, increases abundance, increases expression, decreases expression, affects methylation	2
Cadmium	increases abundance, increases expression	2
Valproic Acid	decreases expression, decreases methylation	2
aristolochic acid I	increases expression	1
FR900359	increases phosphorylation	1
bisphenol F	decreases expression, affects cotreatment	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects expression	1
sodium arsenate	decreases expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, affects localization, decreases expression	1
beta-lapachone	increases expression	1
arsenite	affects binding, increases reaction	1
lead chloride	increases expression	1
cupric oxide	increases expression	1
4-aminophenylarsenoxide	affects binding, decreases reaction	1
methacrylaldehyde	affects cotreatment, increases oxidation	1
beta-methylcholine	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
azoxystrobin	increases expression	1
deguelin	increases expression	1
K 7174	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	decreases expression	1
pyrimidifen	increases expression	1
nutlin 3	affects cotreatment, increases secretion	1
abrine	increases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4270828	Binding	Binding affinity to elongation factor 1-beta in human Hela cells lysates assessed as protein enrichment by measuring normalized heavy/light ratio at by nano-LC-ESIMS/MS analysis	Determination of Gymnemic Acid I as a Protein Biosynthesis Inhibitor Using Chemical Proteomics. — J Nat Prod

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2W9	Abcam HEK293T EEF1B2 KO	Transformed cell line	Female

Clinical trials (associated diseases)

390 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays